Teva could now be in line for the world’s first launch of a biosimilar rival to Lucentis (ranibizumab), after the UK’s Medicines & Healthcare Regulatory Agency approved the Ongavia version that was developed by Bioeq and Formycon under the FYB201 designation.
Under an exclusive commercialization deal struck last year, Teva has rights to FYB201 in Europe, as well as Canada, Israel,...






